New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
07:59 EDTPRTAProthena data somewhat misunderstood by investors, says RBC Capital
RBC Capital believes the pullback in Prothena's stock reflected some misunderstanding of data on the company's NEOD001, a monoclonal antibody in clinical development for the treatment of patients with AL amyloidosis and persistent organ dysfunction. The firm believes that the data indicates that the drug is having a real impact. It keeps a $52 price target and Outperform rating on the stock.
News For PRTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
07:22 EDTPRTAUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link
May 13, 2015
17:10 EDTPRTAProthena to present updated NEOD001 data at 2015 ASCO annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use